You have read all your free articles, to continue reading subscribe to read the rest of this content.
Sigrid Therapeutics has announced that the results from their Proof-of-Concept STAR study have been published in Nanomedicine. Oral administration of the company’s lead product SiPore15 to subjects with prediabetes or newly diagnosed type 2 diabetes resulted in a significant and clinically meanAlready a subscriber Login You have read all your…
BioInvent International has announced the completion of the planned dose escalation part of its Phase 1/2a trial of the anti-TNFR2 drug candidate BI-1808. Given the positive safety and tolerability profile observed so far, a higher dose of BI-1808 as single agent will be tested to explore the effAlready a subscriber…
Nordic Nanovector has provided an update on PARADIGME, its Phase 2b trial of Betalutin in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma. Following a comprehensive review and independent data evaluation of PARADIGME and a subsequent request for regulatory agency interaction, the BAlready a subscriber Login You have read all your…
AstraZeneca and Eli Lilly and Company are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer’s disease. The decision is based on recommendations by an independent data monitoring committee (Already a subscriber Login You have read all…
